Literature DB >> 21126839

Comparison of 3D two-point Dixon and standard 2D dual-echo breath-hold sequences for detection and quantification of fat content in renal angiomyolipoma.

Andrew B Rosenkrantz1, Sean Raj, James S Babb, Hersh Chandarana.   

Abstract

PURPOSE: To assess the utility of a 3D two-point Dixon sequence with water-fat decomposition for quantification of fat content of renal angiomyolipoma (AML).
METHODS: 84 patients underwent renal MRI including 2D in-and-opposed-phase (IP and OP) sequence and 3D two-point Dixon sequence that generates four image sets [IP, OP, water-only (WO), and fat-only (FO)] within one breath-hold. Two radiologists reviewed 2D and 3D images during separate sessions to identify fat-containing renal masses measuring at least 1cm. For identified lesions subsequently confirmed to represent AML, ROIs were placed at matching locations on 2D and 3D images and used to calculate 2D and 3D SI(index) [(SI(IP)-SI(OP))/SI(IP)] and 3D fat fraction (FF) [SI(FO)/(SI(FO)+SI(WO))]. 2D and 3D SI(index) were compared with 3D FF using Pearson correlation coefficients.
RESULTS: 41 AMLs were identified in 6 patients. While all were identified using the 3D sequence, 39 were identified using the 2D sequence, with the remaining 2 AMLs retrospectively visible on 2D images but measuring under 1cm. Among 32 AMLs with a 3D FF of over 50%, both 2D and 3D SI(index) showed a statistically significant inverse correlation with 3D FF (2D SI(index): r=-0.63, p=0.0010; 3D SI(index): r=-0.97, p<0.0001).
CONCLUSION: 3D two-point Dixon sequence may provide a reasonable alternative to 2D dual-echo sequence for detection of renal AML and may have additional value for quantification of fat content of these lesions given the observation that 3D FF, unlike 2D and 3D SI(index), is not limited by ambiguity of water or fat dominance. This may assist clinical management of AML given evidence that fat content predicts embolization response.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21126839     DOI: 10.1016/j.ejrad.2010.11.012

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  7 in total

Review 1.  Renal relevant radiology: renal functional magnetic resonance imaging.

Authors:  Behzad Ebrahimi; Stephen C Textor; Lilach O Lerman
Journal:  Clin J Am Soc Nephrol       Date:  2013-12-26       Impact factor: 8.237

2.  Renal and adrenal masses containing fat at MRI: Proposed nomenclature by the society of abdominal radiology disease-focused panel on renal cell carcinoma.

Authors:  Nicola Schieda; Matthew S Davenport; Ivan Pedrosa; Atul Shinagare; Hersch Chandarana; Nicole Curci; Ankur Doshi; Gary Israel; Erick Remer; Jane Wang; Stuart G Silverman
Journal:  J Magn Reson Imaging       Date:  2019-01-28       Impact factor: 4.813

Review 3.  How We Do It: Managing the Indeterminate Renal Mass with the MRI Clear Cell Likelihood Score.

Authors:  Ivan Pedrosa; Jeffrey A Cadeddu
Journal:  Radiology       Date:  2021-12-14       Impact factor: 29.146

4.  In Vivo Renal Lipid Quantification by Accelerated Magnetic Resonance Spectroscopic Imaging at 3T: Feasibility and Reliability Study.

Authors:  Ahmad A Alhulail; Mahsa Servati; Nathan Ooms; Oguz Akin; Alp Dincer; M Albert Thomas; Ulrike Dydak; Uzay E Emir
Journal:  Metabolites       Date:  2022-04-23

Review 5.  Imaging and Screening of Kidney Cancer.

Authors:  Alberto Diaz de Leon; Ivan Pedrosa
Journal:  Radiol Clin North Am       Date:  2017-11       Impact factor: 2.303

Review 6.  MRI phenotype in renal cancer: is it clinically relevant?

Authors:  Naomi Campbell; Andrew B Rosenkrantz; Ivan Pedrosa
Journal:  Top Magn Reson Imaging       Date:  2014-04

7.  New MRI series for kidney evaluation: Saving time and money.

Authors:  Matteo Renzulli; Stefano Brocchi; Irene Pettinari; Maurizio Biselli; Alfredo Clemente; Beniamino Corcioni; Salvatore Cappabianca; Caterina Gaudiano; Rita Golfieri
Journal:  Br J Radiol       Date:  2019-06-12       Impact factor: 3.039

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.